Experimental scrutiny and project timelines

an example

Research output: Contribution to journalArticle

150 Downloads (Pure)

Abstract

AZD0424 (Fig. 1) is a dual selective inhibitor of Src and Abl non-receptor tyrosine kinases being developed for clinical trial through a partnership between AstraZeneca and Cancer Research UK. Formulation, pre-formulation and development studies were performed at the Cancer Research UK Formulation Unit at the University of Strathclyde. Here the authors report an example where the proper use and interpretation of ‘forced degradation’ experiments (performed during the early development stages of a drug project) allowed analysts to quickly identify problems occurring at subsequent stages.
Original languageEnglish
Pages (from-to)1208-1209
Number of pages2
JournalJournal of Pharmacy and Pharmacology
Volume62
Issue number10
DOIs
Publication statusPublished - Oct 2010

Fingerprint

src-Family Kinases
Research
Neoplasms
Clinical Trials
Pharmaceutical Preparations
TimeLine

Keywords

  • tyrosine kinases
  • cancer research
  • experimental analysis

Cite this

@article{2bfc172567db41fcab6c1a72018c21a2,
title = "Experimental scrutiny and project timelines: an example",
abstract = "AZD0424 (Fig. 1) is a dual selective inhibitor of Src and Abl non-receptor tyrosine kinases being developed for clinical trial through a partnership between AstraZeneca and Cancer Research UK. Formulation, pre-formulation and development studies were performed at the Cancer Research UK Formulation Unit at the University of Strathclyde. Here the authors report an example where the proper use and interpretation of ‘forced degradation’ experiments (performed during the early development stages of a drug project) allowed analysts to quickly identify problems occurring at subsequent stages.",
keywords = "tyrosine kinases , cancer research, experimental analysis",
author = "N. Dooley and Ford, {S. J.} and Elke Prasad and M. Elliott and Gavin Halbert",
note = "ABSTRACTS FROM THE UK-PHARMSCI CONFERENCE, 1–3 SEPTEMBER 2010",
year = "2010",
month = "10",
doi = "10.1111/j.2042-7158.2010.01178.x",
language = "English",
volume = "62",
pages = "1208--1209",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
number = "10",

}

Experimental scrutiny and project timelines : an example. / Dooley, N.; Ford, S. J.; Prasad, Elke; Elliott, M.; Halbert, Gavin.

In: Journal of Pharmacy and Pharmacology, Vol. 62, No. 10, 10.2010, p. 1208-1209.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Experimental scrutiny and project timelines

T2 - an example

AU - Dooley, N.

AU - Ford, S. J.

AU - Prasad, Elke

AU - Elliott, M.

AU - Halbert, Gavin

N1 - ABSTRACTS FROM THE UK-PHARMSCI CONFERENCE, 1–3 SEPTEMBER 2010

PY - 2010/10

Y1 - 2010/10

N2 - AZD0424 (Fig. 1) is a dual selective inhibitor of Src and Abl non-receptor tyrosine kinases being developed for clinical trial through a partnership between AstraZeneca and Cancer Research UK. Formulation, pre-formulation and development studies were performed at the Cancer Research UK Formulation Unit at the University of Strathclyde. Here the authors report an example where the proper use and interpretation of ‘forced degradation’ experiments (performed during the early development stages of a drug project) allowed analysts to quickly identify problems occurring at subsequent stages.

AB - AZD0424 (Fig. 1) is a dual selective inhibitor of Src and Abl non-receptor tyrosine kinases being developed for clinical trial through a partnership between AstraZeneca and Cancer Research UK. Formulation, pre-formulation and development studies were performed at the Cancer Research UK Formulation Unit at the University of Strathclyde. Here the authors report an example where the proper use and interpretation of ‘forced degradation’ experiments (performed during the early development stages of a drug project) allowed analysts to quickly identify problems occurring at subsequent stages.

KW - tyrosine kinases

KW - cancer research

KW - experimental analysis

U2 - 10.1111/j.2042-7158.2010.01178.x

DO - 10.1111/j.2042-7158.2010.01178.x

M3 - Article

VL - 62

SP - 1208

EP - 1209

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 10

ER -